Results 71 to 80 of about 54,639 (294)

Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura

Haematologica, 2014
Anti-ADAMTS13 autoantibodies are the main cause of acquired thrombotic thrombocytopenic purpura. Binding of these antibodies to ADAMTS13 eventually results in the formation of antigen-antibody immune complexes.
Silvia Ferrari, Kristina Palavra, Bernadette Gruber, Johanna A. Kremer Hovinga, Paul Knöbl, Claudine Caron, Caroline Cromwell, Louis Aledort, Barbara Plaimauer, Peter L. Turecek, Hanspeter Rottensteiner, Friedrich Scheiflinger   +11 more
doaj   +1 more source

Utility of Immature Platelet Fraction as Diagnostic Biomarker for Isolated Thrombocytopenia

Pakistan Armed Forces Medical Journal, 2023
Objective: To evaluate the utility of immature platelet fraction (IPF) as a marker in immune thrombocytopenia purpura (ITP) patients. Study Design: Comparative cross-sectional study. Place and Duration of Study: Department of Haematology, Chughtai
Zahra Rashid Khan, Ayisha Imran, N.A.Malik   +2 more
doaj   +1 more source

Efficacy and Safety of Rituximab in Connective Tissue Disease‐Associated Thrombotic Thrombocytopenic Purpura/Thrombotic Microangiopathy

International Journal of Rheumatic Diseases, Volume 28, Issue 6, June 2025.
ABSTRACT Introduction This study examined the efficacy and safety of Rituximab (RTX) treatment in connective tissue disease (CTD)‐associated thrombocytopenic purpura (TTP) and thrombotic microangiopathy (TMA), using historical controls as comparators.
Naoaki Ohkubo, Shingo Nakayamada, Shunsuke Fukuyo, Yusuke Miyazaki, Yoshino Inoue, Hiroaki Tanaka, Yasuyuki Todoroki, Yoshiya Tanaka   +7 more
wiley   +1 more source

Does Gestational Thrombocytopenia and Immune Thrombocytopenic Purpura Warrant Hospital Admission?

Pakistan Armed Forces Medical Journal
Objective: To determine the severity of thrombocytopenia in pregnancy and manage gestational thrombocytopenia patients in the outpatient department in order to reduce the economic burden on hospitals. Study Design: Cross-sectional study.
Ayesha Ellahi, Ayesha Nayyar, Maham Arshad, Wasiullah Khan, Afnan Naeem, Warda Furqan   +5 more
doaj   +1 more source

Successful treatment of a patient with herbal drug-induced immune thrombocytopenic purpura using freshly donated blood

Universa Medicina, 2018
Background Drug-induced thrombocytopenia (DITP), which also includes thrombocytopenia induced by beverages, foods, and herbal remedies, is an important clinical problem for haematologists.
Marcellinus Uchechukwu Nwagu
doaj   +1 more source

Modern concepts of the platelet in health and disease [PDF]

, 1962
Thesis (M.D.)--Boston ...
Estes, J. Worth
core  

Management of Immune Thrombocytopenic Purpura in Adults [PDF]

Mayo Clinic Proceedings, 2004
Primary immune thrombocytopenic purpura (ITP), also referred to as idiopathic thrombocytopenic purpura, is an organ-specific autoimmune disorder in which antibody-coated or immune complex-coated platelets are destroyed prematurely by the reticuloendothelial system, resulting in peripheral blood thrombocytopenia. The disease is heterogeneous with regard
Stasi, Roberto, Provan, Drew
openaire   +4 more sources

Profound Thrombocytopenia and Dyspnea 11 Days After Cardiac Surgery

American Journal of Hematology, Volume 100, Issue 7, Page 1234-1239, July 2025.
Sebastian Vuong, Menaka Pai, Sarah Patterson, Theodore E. Warkentin   +3 more
wiley   +1 more source

Impact of COVID‐19 on paediatric care in Japan: Analysis of national health insurance claims data

Acta Paediatrica, Volume 114, Issue 6, Page 1135-1142, June 2025.
Abstract Aim To quantify the impact of the COVID‐19 pandemic on paediatric care use compared to adult care and identify affected subdomains. Methods Data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) for six fiscal years (FY2016‐2021) were analysed.
Takuma Ohnishi, Mari Kinoshita, Satoshi Narumi   +2 more
wiley   +1 more source

How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance

British Journal of Haematology, Volume 206, Issue 6, Page 1560-1570, June 2025.
The use of rituximab as a pre‐emptive treatment in immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is the current standard of care. However, for patients refractory to rituximab or for those with contraindication, further treatment guidelines are scarce.
Julia Weisinger, Jehane Fadlallah, Bérangère Joly, Agnès Veyradier, Paul Coppo   +4 more
wiley   +1 more source